Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30987312 | 0.86 | CYP3A4 (0.42) | ALDH1A1MAPK1 | |
| SCHEMBL24878867 | 0.86 | CYP3A4 (0.42) | ALDH1A1MAPK1 | |
| SCHEMBL27457195 | 0.86 | ALDH1A1 (0.31) | ALDH1A1MAPK1 | |
| SCHEMBL24879349 | 0.76 | KDM4E (0.40) | ALDH1A1 | |
| SCHEMBL24878907 | 0.73 | CYP3A4 (0.37) | ALDH1A1MAPK1 | |
| SCHEMBL27458190 | 0.73 | PARP1 (0.39) | ALDH1A1 | |
| SCHEMBL31723337 | 0.71 | CYP3A4 (0.42) | ALDH1A1MAPK1 | |
| SCHEMBL21154729 | 0.69 | CYP3A4 (0.46) | ALDH1A1MAPK1 | |
| SCHEMBL27453451 | 0.68 | TNF (0.41) | ALDH1A1MAPK1 | |
| SCHEMBL19785248 | 0.68 | CYP3A4 (0.50) | ALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | ALDH1A1 3565/4885MAPK1 272/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.